Search | WHO COVID-19 Research Database

Pediatric Dosing Errors during a National Shortage of Fever and Pain Medications.

Zipursky, Jonathan S; Brown, Kevin A; Khan, Sara; Cohen, Eyal; Burke, Jacqueline; Austin, Emily; Stall, Nathan M.

N Engl J Med ; 388(22): 2099-2101, 2023 Jun 01.

Article in English | MEDLINE | ID: covidwho-20245437

Subject(s)

Analgesics , Antipyretics , Medication Errors , Pain , Child , Humans , Pain/drug therapy , Fever/drug therapy , Antipyretics/administration & dosage , Antipyretics/supply & distribution , Antipyretics/therapeutic use , Analgesics/administration & dosage , Analgesics/supply & distribution , Analgesics/therapeutic use , Canada/epidemiology

Fluvoxamine pour les patients atteints de COVID-19 non hospitalisés.

Wu, Peter E; Austin, Emily; Leong, Derek.

CMAJ ; 194(11): E437-E438, 2022 03 21.

Article in French | MEDLINE | ID: covidwho-2089470

Subject(s)

Antidepressive Agents, Second-Generation , COVID-19 Drug Treatment , Fluvoxamine , Humans , Selective Serotonin Reuptake Inhibitors

Does ketamine provide a shorter time to sedation when compared to haloperidol and midazolam in the agitated ED patient?

Kent, Jessica; Austin, Emily; Nolan, Brodie.

CJEM ; 24(2): 133-134, 2022 03.

Article in English | MEDLINE | ID: covidwho-1748353

Subject(s)

Ketamine , Midazolam , Anesthetics, Dissociative/therapeutic use , Haloperidol/therapeutic use , Humans , Hypnotics and Sedatives/therapeutic use , Ketamine/therapeutic use , Midazolam/therapeutic use

Fluvoxamine for symptomatic outpatients with COVID-19: CMAJ

Wu, Peter E. M. D. MSc, Austin, Emily M. D.; Leong, Derek RPh BScPhm.

Canadian Medical Association. Journal ; 194(7), 2022.

Article in English | ProQuest Central | ID: covidwho-1711086

ABSTRACT

Five things to know about fluvoxamine for symptomatic outpatients with COVID-19 are presented.

Fluvoxamine for symptomatic outpatients with COVID-19.

Wu, Peter E; Austin, Emily; Leong, Derek.

CMAJ ; 194(7): E258, 2022 02 22.

Article in English | MEDLINE | ID: covidwho-1639151

Subject(s)

COVID-19 Drug Treatment , Fluvoxamine/administration & dosage , Selective Serotonin Reuptake Inhibitors/administration & dosage , Adult , Fluvoxamine/adverse effects , Humans , SARS-CoV-2 , Selective Serotonin Reuptake Inhibitors/adverse effects

Subject(s)

Subject(s)

Subject(s)

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL